Nicotinic acetylcholine receptors, or nAChRs, are receptor polypeptides that respond to the neurotransmitter acetylcholine. Nicotinic receptors also respond to drugs such as the agonist nicotine. They are found in the central and peripheral nervous system + some more technical info. Structurally nAChRs are pentameric ligand gated ion channels in the cys-loop receptor family, assembled from distinct alpha and non-alpha subunits encoded by CHRNA and CHRNB gene families to form neuronal and muscle subtype variants. Activation opens a nonselective cation pore that permits Na and K flux and in many subtypes permits significant Ca entry, coupling fast synaptic transmission to intracellular signaling pathways. Subunit composition determines single channel conductance, agonist sensitivity, desensitization kinetics and pharmacology; common neuronal assemblies include alpha4beta2 and alpha7 homomers, while the adult neuromuscular receptor contains alpha1, beta1, delta and epsilon subunits. nAChRs are modulated by competitive antagonists, noncompetitive pore blockers and positive and negative allosteric modulators, and are validated targets for therapies addressing nicotine dependence, cognitive disorders, pain modulation and neuromuscular blockade in clinical anesthesia.
For purified nicotine preparations used in pharmaceutical and laboratory settings typical purity specifications target greater than 99.0 percent assay for the parent alkaloid with total related alkaloid impurities kept to low hundreds to low thousands of parts per million. Common related alkaloids and impurities observed by GC-MS or LC-MS include nornicotine, anabasine, anatabine, myosmine, nicotine N-oxide and minor lactam or oxidation products; individual related compounds in high grade material are often below 1000 ppm and frequently below 100 ppm, while crude tobacco extracts can contain several alkaloids at the 0.1 to 1.0 percent level depending on source and processing. Typical analytical control strategies report limits for key impurities, a total related compounds limit, and methods such as validated HPLC-UV, LC-MS/MS or GC-MS for identity and quantitation to ensure batch to batch consistency and to monitor oxidative or thermal degradation products.
Nicotinic drugs comprise agonists, partial agonists, antagonists and allosteric modulators that act at nAChRs; clinical and research uses include smoking cessation aids, cognitive enhancers in experimental or adjunctive treatment of neurodegenerative and neuropsychiatric conditions, analgesics or adjuvants for certain pain states, and neuromuscular blocking agents in anesthesia. Preclinical and translational work also targets nAChRs for inflammation modulation and metabolic regulation.
Nicotinic receptors are ligand gated ion channels that mediate fast synaptic currents through direct opening of a cation pore when acetylcholine or an agonist binds, whereas muscarinic receptors are G protein coupled receptors that produce slower, metabotropic responses via intracellular second messenger cascades. Nicotinic signaling is typically rapid and ionotropic, muscarinic signaling is slower and modulatory, and the two receptor classes have distinct tissue distributions and pharmacology.
The nicotinic effect refers to acute activation of nAChRs leading to membrane depolarization from Na and sometimes Ca influx, increased neurotransmitter release at presynaptic sites, modulation of neuronal excitability, and downstream calcium dependent signaling. Chronically or at high agonist exposure, nAChRs may desensitize or undergo regulatory changes that alter synaptic responsiveness and receptor expression.
Nicotinic agents are used experimentally and clinically to modify cholinergic signaling via nAChRs for indications such as facilitating smoking cessation, probing cognitive processes, treating certain neuromuscular conditions with blockers during surgery, and exploring potential benefits in pain and inflammatory disorders; selection of a specific nicotinic agent depends on desired receptor subtype selectivity, agonist versus antagonist action, and acceptable safety and pharmacokinetic profiles.
